ES2325938B1 - USE OF PLATES TO MANUFACTURE A MEDICINAL PRODUCT FOR THE TREATMENT OF EYE PATHOLOGIES - Google Patents
USE OF PLATES TO MANUFACTURE A MEDICINAL PRODUCT FOR THE TREATMENT OF EYE PATHOLOGIES Download PDFInfo
- Publication number
- ES2325938B1 ES2325938B1 ES200700581A ES200700581A ES2325938B1 ES 2325938 B1 ES2325938 B1 ES 2325938B1 ES 200700581 A ES200700581 A ES 200700581A ES 200700581 A ES200700581 A ES 200700581A ES 2325938 B1 ES2325938 B1 ES 2325938B1
- Authority
- ES
- Spain
- Prior art keywords
- plasma
- treatment
- application
- platelets
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000000699 topical effect Effects 0.000 claims description 9
- 239000003634 thrombocyte concentrate Substances 0.000 claims description 7
- 230000008595 infiltration Effects 0.000 claims description 6
- 238000001764 infiltration Methods 0.000 claims description 6
- 230000007170 pathology Effects 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000007850 degeneration Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 208000030533 eye disease Diseases 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 4
- 230000004075 alteration Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 206010015911 Eye burns Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000013490 limbo Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- -1 provitamins Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008403 visual deficit Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Uso de plaquetas para fabricar un medicamento para el tratamiento de patologías oculares.Use of platelets to make a medicine for the treatment of eye diseases.
Uso de plaquetas plasmáticas para la elaboración de un medicamento para aplicación y tratamiento de enfermedades, infecciones, degeneraciones, distrofias, lesiones y trasplantes oculares y perioculares.Use of plasma platelets for processing of a medicine for the application and treatment of diseases, infections, degenerations, dystrophies, lesions and transplants ocular and periocular.
Description
Uso de plaquetas para fabricar un medicamento para el tratamiento de patologías oculares.Use of platelets to make a medicine for the treatment of eye diseases.
Es conocida, desde hace tiempo que la aplicación subconjuntival de sangre directa en el ojo mejora el pronóstico de las quemaduras oculares (1, 2). Aunque también con incovenientes como la importante quemosis residual que llega a provocar alteraciones en la córnea por la irregularidad de lubrificación de la superficie ocular y déficit del cierre palpebral, entre otros. Así mismo se aumenta, más si cabe, el estado de ansiedad del paciente por el aspecto físico que deja tras su aplicación.It has been known for some time that the application direct blood subconjunctival in the eye improves the prognosis of eye burns (1, 2). Although also with inconveniences as the important residual chemosis that causes alterations in the cornea due to the irregularity of lubrication of the ocular surface and deficit of the eyelid closure, among others. Likewise, the anxiety state of the patient because of the physical aspect he leaves after his application.
Hemos encontrado que la fracción activa de la sangre en dicho tratamiento se localiza en las plaquetas, por lo que hemos aplicado subconjuntival y tópicamente concentrado de plaquetas plasmáticas, obteniendo un tiempo de quemosis inferior a 24 hs, cierre palpebral completo, desapareciendo las alteraciones corneales y disminuyendo el estado de ansiedad del paciente y no encontrando déficit visual en el paciente. Así como mayor recuperación de las alteraciones de la superficie ocular que con tratamiento médicos convencionales. El contenido de las plaquetas permiten activar mecanismo de defensa antiinflamatorios, antiinfecionsos, reparadores e incluso facilitar la adaptación de injertos y trasplantes, lo cual hemos podido comprobar en limbo esclerocorneal y en procesos infecciosos e inflamatorios oftalmológicos. Dicha aplicación es un tratamiento fácil, sencillo, económico y reproducible.We have found that the active fraction of the blood in said treatment is located in the platelets, so that we have applied subconjunctival and topically concentrated of plasma platelets, obtaining a chemosis time less than 24 hours, full eyelid closure, disappearing alterations corneal and decreasing the patient's anxiety state and not finding visual deficit in the patient. As well as older recovery of alterations of the ocular surface that with Conventional medical treatment The content of platelets allow to activate anti-inflammatory defense mechanism, anti-infections, repairers and even facilitate the adaptation of grafts and transplants, which we have been able to verify in limbo sclerocorneal and in infectious and inflammatory processes ophthalmological This application is an easy, simple treatment, Economical and reproducible.
Uso de concentrado de plaquetas plasmáticas no precipitadas para la aplicación subconjuntival, subtenoniana, palpebral, orbitaria, limbar, escleral, corneal, tópica sobre la lágrima y superficie ocular para el tratamiento de enfermedades, infecciones, degeneraciones, distrofias, lesiones y trasplantes oculares parciales o totales, también podría ser reproducible su utilización en cualquier parte del cuerpo. El concentrado plaquetario puede aplicarse sólo o junto a otras sustancias.Use of non-plasma platelet concentrate precipitates for subconjunctival, subtenonian application, palpebral, orbital, limbar, scleral, corneal, topical on the tear and ocular surface for the treatment of diseases, infections, degenerations, dystrophies, lesions and transplants partial or total eyepieces, it could also be reproducible use in any part of the body. The concentrate Platelet can be applied alone or together with other substances.
El método de obtención es la extracción de sangre del propio paciente o de un banco de sangre. La sangre, que puede ser sangre venosa periférica, se deposita en tubos estériles de unos 4,5 ml o similar, se anticoagula con sustancias que no precipiten las plaquetas (como el citrato sódico al 10%). Se obtiene de 9 a 30 cm^{3} de sangre y se centrifuga a temperatura ambiente, a 300 G durante 7 minutos (se puede aumentar o disminuir el tiempo y la velocidad de centrifugación en función de las necesidades: 250-350 G y 5-10 minutos). La centrifugación separa los glóbulos rojos (parte inferior y de color rojo del tubo) del plasma (parte superior y amarillenta).The method of obtaining is the extraction of blood of the patient or a blood bank. The blood, which it can be peripheral venous blood, it is deposited in sterile tubes of about 4.5 ml or similar, it is anticoagulated with substances that do not precipitate platelets (such as 10% sodium citrate). Be gets 9 to 30 cm 3 of blood and centrifuges at temperature ambient, at 300 G for 7 minutes (can be increased or decreased the time and speed of centrifugation depending on the needs: 250-350 G and 5-10 minutes) Centrifugation separates the red blood cells (part bottom and red tube) of plasma (top and yellowish).
A su vez, se extrae la fracción plasmática con mayor concentrado de plaquetas, que se encuentra en el sobrenadante inmediato a la fracción de la serie roja, mediante micropipetas manuales automáticas o cualquier otra técnica al efecto. El líquido o suspensión resultante se aplica directa y localmente (infiltración o tópico) en la zona ocular a tratar y definida previamente. Para su aplicación, las plaquetas no deben estar precipitadas. No hace falta añadir ningún producto o sustancia para agregar o precipitar las plaquetas, que se liberarán espontáneamente con el propio contacto con los tejidos y estructuras. Si bien puede ser aplicado junto a otras sustancias que puedan potenciar la curación tales como antibióticos, antiinflamatorios, anestésicos, vitaminas, provitaminas, metabolitos, prometabolitos, plasma, sueros, neuropéptidos, etcétera. El concentrado de plaquetas plasmáticas puede aplicarse directamente sólo o diluirse con diferentes concentraciones de plasma, suero u otras sustancias y/o medios afines ya referidos. Su aplicación es local (tópica, infiltración,...).In turn, the plasma fraction is extracted with highest platelet concentrate, found in the immediate supernatant to the fraction of the red series, by automatic manual micropipettes or any other technique at effect. The resulting liquid or suspension is applied directly and locally (infiltration or topical) in the eye area to be treated and previously defined. For application, platelets should not be hasty No need to add any product or substance to add or precipitate platelets, which will be released spontaneously with your own contact with the tissues and structures Although it can be applied together with other substances that can enhance healing such as antibiotics, anti-inflammatories, anesthetics, vitamins, provitamins, metabolites, promethabolites, plasma, sera, neuropeptides, etc. The plasma platelet concentrate can be applied directly alone or diluted with different concentrations of plasma, serum or other related substances and / or related media. its application is local (topical, infiltration, ...).
Para infiltración se recomienda la utilización de alrededor de 1 cc (de 0,50 a 2 cm^{3}) de concentrado de plaquetas obtenidos, principalmente de los 0,250 cc del plasma sobrenadante de los tubos de 4,5 ml, zona de máxima concentración pudiendo aplicarse subconjuntival, tenoniana, epiescleral, subtarsal, intrapalpebral y orbitaria.For infiltration the use is recommended about 1 cc (0.50 to 2 cm 3) of concentrate of platelets obtained, mainly from 0.250 cc of plasma 4.5 ml tube supernatant, zone of maximum concentration being able to apply subconjunctival, tenonian, episcleral, subtarsal, intrapalpebral and orbital.
Puede utilizarse sólo o junto a otras sustancias, antibióticos, antiinflamatorios, anestésicos, etcétera. En función de las necesidades, puede repetirse el tratamiento tantas veces como sea necesario. Así mismo, si se quiere obtener una concentración mayor de plaquetas en un menor volumen se vuelve a centrifugar.It can be used alone or with others substances, antibiotics, anti-inflammatories, anesthetics, etc. Depending on the needs, the treatment can be repeated As many times as needed. Likewise, if you want to get a higher concentration of platelets in a smaller volume becomes to centrifuge
Para la aplicación tópica, dependiendo del cuadro a tratar, puede utilizarse todo el plasma obtenido o las fracciones con más concentración de plaquetas, de 0,5-1 cm^{3} del plasma que se encuentra sobre la fracción de glóbulos rojos. Dicho concentrado plaquetario plasmático puede aplicarse directamente o diluido en suero u otras sustancias o compuestos anteriormente citados.For topical application, depending on the table to be treated, all the plasma obtained or the fractions with more platelet concentration, of 0.5-1 cm3 of the plasma on the fraction of red blood cells. Said platelet concentrate Plasma can be applied directly or diluted in serum or other substances or compounds mentioned above.
Los concentrados de plaquetas se pueden conservar a una temperatura de 4ºC hasta un máximo de 30 días y a -4ºC o menos durante 2 a 3 meses. Debe conservarse fuera de la acción de la luz ya que alteraría el producto, por posible desnaturalización de plaquetas y proteinas. Para colirios pueden utilizarse frascos estériles con dosificadores al efecto con contenido para 5 ml, por ejemplo.Platelet concentrates can be keep at a temperature of 4ºC up to a maximum of 30 days and at -4 ° C or less for 2 to 3 months. It must be kept out of the light action as it would alter the product, as possible denaturation of platelets and proteins. For eye drops can use sterile bottles with dispensers for that purpose with content for 5 ml, for example.
Para aplicación tópica se recomienza que sea sobre el fondo de saco inferior de conjuntiva 1-2 gotas por instilación, cada 3 horas, pudiendo varias la pauta y la concentración del medicamento en función de las patologías a tratar. El concentrado de plaquetas plasmáticas puede aplicarse directamente (topico e infiltración) o diluirse (tópico) del 20 al 100% en suero u otros medios.For topical application it is recommended that it be on the bottom of the lower sac of conjunctiva 1-2 drops by instillation, every 3 hours, being able to several the pattern and the concentration of the drug depending on the pathologies to try. The plasma platelet concentrate can be applied directly (topical and infiltration) or diluted (topical) from 20 to 100% serum or other media.
Algunos de los medios pueden ser geles o ungüentos, pero éstos nunca contendrán sustancias que hagan precipitar las plaquetas.Some of the media can be gels or ointments, but these will never contain substances that make precipitate platelets
1. Salay S, Feher J, Podhoranyi G. Experience with autologous blood therapy in burns. Klin Monatsbl Augenheilkd. 1967; 150 (6): 879-86.1. Salay S, Feher J, Podhoranyi G. Experience with autologous blood therapy in burns. Klin Monatsbl Augenheilkd . 1967 ; 150 (6): 879-86.
2. Dolelazova, V. Kutskova, L. Subconjunctival injection of autogenous blood in the eye after thermical and chemical burns. Cesk. Oftalmol. 1973. May; 29 (3): 207-12.2. Dolelazova , V. Kutskova , L. Subconjunctival injection of autogenous blood in the eye after thermical and chemical burns. Cesk Ophthalmol 1973 May; 29 (3): 207-12.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200700581A ES2325938B1 (en) | 2007-02-27 | 2007-02-27 | USE OF PLATES TO MANUFACTURE A MEDICINAL PRODUCT FOR THE TREATMENT OF EYE PATHOLOGIES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200700581A ES2325938B1 (en) | 2007-02-27 | 2007-02-27 | USE OF PLATES TO MANUFACTURE A MEDICINAL PRODUCT FOR THE TREATMENT OF EYE PATHOLOGIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2325938A1 ES2325938A1 (en) | 2009-09-24 |
| ES2325938B1 true ES2325938B1 (en) | 2010-07-23 |
Family
ID=41065903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200700581A Expired - Fee Related ES2325938B1 (en) | 2007-02-27 | 2007-02-27 | USE OF PLATES TO MANUFACTURE A MEDICINAL PRODUCT FOR THE TREATMENT OF EYE PATHOLOGIES |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2325938B1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811777B2 (en) * | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
| ES2221770B2 (en) * | 2002-04-19 | 2006-07-16 | Eduardo Anitua Aldecoa | METHOD OF PREPARATION OF A COMPOUND FOR THE REGENERATION OF FABRICS. |
| ES2262444B1 (en) * | 2006-03-01 | 2007-12-16 | Universidad De Leon | USE OF PLASMA RICH IN PLATES FOR THE PREPARATION OF A MEDICINAL PRODUCT TO COMBAT FRIBROSIS. |
-
2007
- 2007-02-27 ES ES200700581A patent/ES2325938B1/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| GOTO, E. y col. Treatment of superior limbic keratoconjuncyivitis by application of autologous serum. Cornea. 2001, Vol. 20, N$^{o}$ 8, páginas 807-810. Todo el documento. * |
| HARTWIG, D. y col. Topical treatment of ocular surface defects: comparison of the epitheliotrophic capacity of fresh frozen plasma and serum on corneal epithelial cells in a in vitro cell culture model. Transfusion Medicine. 2005, Vol. 15, páginas 107-113. Todo el documento. * |
| MARQUEZ DE ARACENA, R. y col. Tratamiento con concentrado plaquetario plasmático subconjuntival y tópico en el transplante de limbo. Mapfre Medicina. 2006, Vol. 17, N$^{o}$ 4, páginas 280-285. Todo el documento en especial página 284, "{}DISCUSION"{} último párrafo. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2325938A1 (en) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2369945B1 (en) | PROCEDURE FOR OBTAINING A COMPOSITION CONTAINING GROWTH FACTORS FROM A BLOOD COMPOUND, AND COMPOSITION OBTAINABLE BY SUCH PROCEDURE. | |
| US20080299212A1 (en) | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum | |
| US20140358124A1 (en) | Approach to administering ocular medication | |
| ES2325938B1 (en) | USE OF PLATES TO MANUFACTURE A MEDICINAL PRODUCT FOR THE TREATMENT OF EYE PATHOLOGIES | |
| CN104644550A (en) | Curcumin nano micelle eye drops as well as preparation method and application | |
| ES2964629T3 (en) | Eye drops with citric acid as the only active ingredient | |
| ES2552587A2 (en) | Peptide derived from socs1 for use in chronic complications of diabetes (Machine-translation by Google Translate, not legally binding) | |
| CN104606666B (en) | BFGF bovine basic fibroblast growth factor eye drop | |
| US9956254B2 (en) | Extract of taiwanese propolis for treating ocular diseases | |
| WO2017152129A3 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
| Vasileiou et al. | Bilateral vision loss in Waldenstrom’s macroglobulinemia | |
| Garg | Ocular therapeutics | |
| RU2134107C1 (en) | Preparation "gistokhrom" for treatment of eye retina and cornea inflammatory sicknesses | |
| KR100287991B1 (en) | Ophthalmic Argatroban Formulations | |
| Singh et al. | An uncommon presentation of severe falciparum malaria: Acute pancreatitis | |
| KR101794225B1 (en) | Pharmaceutical composition for treatment of corneal endothelial wounds containing angiogenin | |
| Preechawat et al. | Orbital apex syndrome from gnathostomiasis | |
| ES2212907B1 (en) | OPHTHALMOLOGICAL PREPARATIONS BASED ON POVIDONA YODADA. | |
| Capella et al. | Limbal stem cell deficiency following multiple intravitreal injections | |
| US6465506B2 (en) | Instillation techniques for ophthalmic agents to enhance treatment effect | |
| Frost | BSCL therapy for ocular GVHD-a sight for sore eyes | |
| Zakharov et al. | Platelet-rich plasma in macular hole surgery. Literature review | |
| WO2022029113A1 (en) | Composition for treating eye diseases and method of producing same | |
| Sasase et al. | Retinal Ganglion Cell Death of Guinea Pig is Slower Than Rat as Optic Nerve Transection Animal Model | |
| CN115337325A (en) | Stem cell exosome ophthalmic derivative and preparation method of stem cell exosome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20090924 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2325938B1 Country of ref document: ES |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20180912 |